Please assess the completion status of the following clinical trial:

Trial Title: Second Extension Study to Evaluate Safety and Tolerability of Influenza Vaccines in Adults and Elderly, and to Evaluate Immunogenicity and Concomitant Vaccination With Pneumococcal Vaccine in a Subgroup

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* participation in the V58P4 study~* mentally competent to understand the nature, the scope and the consequences of the study~* able and willing to give written informed consent prior to study entry~* available for all the visits scheduled in the study~Exclusion Criteria:~* receipt of another investigational agent within 90 days prior to, or before completion of the safety follow-up period in another study, whichever is longer, prior to Visit 7 and unwilling to refuse participation in another clinical study through the end of the present study~* history of any anaphylaxis, serious vaccine reactions, or allergy to any of the vaccine components~* any acute respiratory disease or infections requiring systemic antibiotic or antiviral therapy (chronic antibiotic therapy for urinary tract prophylaxis was acceptable) or experienced fever (i.e., axillary temperature ≥ 38°C) within the 5 days prior to Visit 7~* pregnant/breast feeding women, or women of childbearing potential who refuse to use a reliable contraceptive method during the three weeks after vaccination

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- cTIV (Type: EXPERIMENTAL): Cell culture derived seasonal trivalent influenza vaccine (cTIV)
- eTIV_a (Type: ACTIVE_COMPARATOR): Influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a)
- FLU (cTIV or eTIV_a) (Type: EXPERIMENTAL): Cell culture derived seasonal trivalent influenza vaccine (cTIV) or influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a).
- FLU (cTIV or eTIV_a) + PV (Type: ACTIVE_COMPARATOR): 23-valent Pneumococcal vaccine (PV) concomitantly administered with cell culture derived seasonal trivalent influenza vaccine (cTIV) or influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a).

Based on this trial design, predict the completion outcome and termination type (if applicable).